Ever since the scandal erupted over compounding pharmacies and a national outbreak of fungal meningitis, KV Pharmaceuticals has been telling the FDA ‘we told you so.’ Now, the drugmaker, which landed in bankruptcy after a pricing controversy over its Makena treatment for premature births caused a ruckus and dramatically slashed sales, is finally experiencing a degree of vindication. For months, KV has been complaining about the quality of some compounded versions of Makena. Specifically, KV has pointed to the troubles at the New England Compounding Center, which was blamed for 741 cases of meningitis, including 55 deaths, and subsequently recalled all of its products, including hydrxyprogesterone caproate, or 17P, which is a compounded version of Makena.